UNSPSC 51422119: Meprednisone disodium phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W80C977F6O, chemically known as pregna-1,4-diene-3,11,20-trione, 17-hydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (16.beta.)-, but more generally known as meprednisone disodium phosphate, which bears US NIH Compound Identifier 31051.

European Medicines Agency schedules meprednisone disodium phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08756MIG. Most nations, for tariff purposes, schedule meprednisone disodium phosphate under HS 29372900. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)C.[NA+].[NA+].

UNSPSC 51422119 Meprednisone disodium phosphate is a Commodity code for a specific corticosteroid pharmaceutical product, but state and local procurement activity under this code does not align with its nominal scope. The single recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS—solicits naloxone and drug deactivation systems, which are emergency response and harm-reduction products unrelated to meprednisone. The mismatch suggests either miscoding in the source data or a one-off tagging anomaly; no corticosteroid pharmaceutical procurement appears in the record.

Seminole County, Florida posted the naloxone and drug deactivation systems procurement on June 30, 2026, with a response deadline of July 26, 2023 (an apparent date discrepancy in the source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carries a two-year initial term with a one-year renewal option, includes probationary termination rights, and requires E-Verify compliance, drug-free workplace certification, and standard commercial insurance. Given the single opportunity and its clear scope mismatch to the code's pharmaceutical definition, this code shows little relevant recent state and local procurement activity.